Kumud Kalia Biography and Net Worth

Insider of Guardant Health

LOCATION

Redwood City, CA, US

WORK

Chief Information Officer @ Guardant Health
Advisor @ PlayPal
Chief Information & Technology Officer @ Cylance, Inc.

Chief Information Officer @ Cylance, Inc.
Chief Information Officer @ Akamai Technologies
VP @ Qwest Communications
CIO @ Dresdner Kleinwort Wasserstein
Consultant @ Self-employed
Technology and Operations Manager @ UBS Investment Bank
Technology Manager @ Morgan Stanley

see less

EDUCATION

University of California, Berkeley

Masters
2019 - 2021
Bangor University

Bachelor of Science (Engineering)
1983 - 1986

SKILLS

Cloud Computing
Enterprise Architecture
Program Management

IT Strategy
Vendor Management
Integration
IT Management
Data Center
Talent Management
Leadership

What is Kumud Kalia's net worth?: The estimated net worth of Kumud Kalia is at least $384,331.62 as of March 18th, 2024. Mr. Kalia owns 12,722 shares of Guardant Health stock worth more than $384,332 as of November 14th. This net worth approximation does not reflect any other investments that Mr. Kalia may own. Learn More about Kumud Kalia's net worth.
How old is Kumud Kalia?: Mr. Kalia is currently 58 years old. There are 7 older executives and no younger executives at Guardant Health. Learn More on Kumud Kalia's age.
How do I contact Kumud Kalia?: The corporate mailing address for Mr. Kalia and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Kumud Kalia's contact information.
Has Kumud Kalia been buying or selling shares of Guardant Health?: Kumud Kalia has not been actively trading shares of Guardant Health within the last three months. Most recently, on Monday, March 18th, Kumud Kalia bought 2,187 shares of Guardant Health stock. The stock was acquired at an average cost of $17.82 per share, with a total value of $38,972.34. Following the completion of the transaction, the insider now directly owns 12,722 shares of the company's stock, valued at $226,706.04. Learn More on Kumud Kalia's trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), and Amirali Talasaz (COO). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, Guardant Health insiders bought shares 1 times. They purchased a total of 2,187 shares worth more than $38,972.34. During the last year, insiders at the sold shares 5 times. They sold a total of 8,996 shares worth more than $246,862.40. The most recent insider tranaction occured on November, 13th when Director Meghan V Joyce sold 2,896 shares worth more than $86,590.40. Insiders at Guardant Health own 5.5% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 11/13/2024.

Kumud Kalia Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2024	Buy	2,187	$17.82	$38,972.34	12,722
12/1/2023	Sell	5,800	$26.37	$152,946.00	5,926
9/12/2023	Sell	2,125	$32.59	$69,253.75	7,813
6/9/2023	Buy	2,981	$32.71	$97,508.51	5,193
11/15/2022	Sell	3,125	$51.87	$162,093.75	20,135
8/17/2022	Sell	2,000	$51.39	$102,780.00	18,530

Kumud Kalia Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $30.21

$30.03

$31.32

50 Day Range

MA: $23.57

$20.20

$31.61

2 Week Range

Now: $30.21

$15.81

$37.04

Volume

2,020,772 shs

Average Volume

2,071,955 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.